Phaseline

Companies › Angiodynamics

Angiodynamics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NanoKnife System
Irreversible electroporation (IRE) device
–Phase 3Stage III Pancreatic Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03899636NanoKnife SystemPhase 3Stage III Pancreatic CancerOncologyApr 2025

From the company's SEC filings

Cash of $34m on 2026-08-31; operating cash outflow about $61m a year; runway about 7 months at that burn, to Mar 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Intensity Therapeutics Can-Fite BioPharma LeonaBio RenovoRx Aura Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.